S. Von Greyerz et al., Degeneracy and additional alloreactivity of drug-specific human alpha beta(+) T cell clones, INT IMMUNOL, 13(7), 2001, pp. 877-885
It has been well established that T cells can recognize small mol. wt compo
unds such as drugs. Results from previous studies revealing a high heteroge
neity and cross-reactivity of drug-specific T cell clones (TCC) in individu
al patients prompted us to analyze the degeneracy of drug-reactive TCR in d
etail. Hence, we analyzed the MHC restriction pattern of a panel of 100 dru
g-specific TCC isolated from different drug-allergic donors. We found that
28 of the tested clones showed an MHC allelle-unrestricted drug recognition
. Most of these clones were at the same time highly drug specific, Le. they
could only be stimulated by the original drug and not by any drug derivati
ves. In contrast, TCC with the ability to interact with different drug deri
vatives displayed a clearly MHC allele-restricted drug recognition. Therefo
re, we concluded that the TCR of these clones is mainly interacting with si
de chains of the appropriate drug molecules and hence able to tolerate alte
rations in the MHC molecule. Moreover, we tested all clones for additional
alloreactivity and found that 27 clones could be stimulated by a self-MHC-p
eptide-drug complex as well as by a non-self-MHC-peptide complex. This cros
s-reactivity with allogeneic MHC molecules was substantially higher in drug
-specific TCC compared to tetanus toxoid-specific clones from the same dono
rs. This suggests that from the point of view of drug-specific TCR, non-sel
f-MHC-peptide complexes have a higher incidence to mimic the 'original' sel
f-MHC-peptide-drug complex and this may occur for TCR recognizing self-MHC-
pathogen-derived peptide complexes. Finally, the biological functions of bi
specific TCC were not influenced by the nature of the stimulating ligand. B
oth drug as well as allogeneic stimulation led to similar reaction patterns
in the analyzed TCC.